Preserving Lung Function in Idiopathic Pulmonary Fibrosis
New England Journal of Medicine · 09.07.2026 · 395 (2) · 189-190
DOI: 10.1056/nejme2606821 ↗Kurz gefasst
Editorial in der Zeitschrift New England Journal of Medicine, erschienen am 09.07.2026. Verfasst von Darren Taichman. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease, with an estimated global yearly incidence of approximately 6 per 100,000 and a prevalence of approximately 18 per 100,000. 1,2 Patients with IPF have progressive dyspnea that is commonly accompanied by a disabling cough, impaired quality of life, and frequent exacerbations that lead to hospitalization. And the disease is deadly, with a median survival of less than 4 years. 1 Antifibrotic agents (e.g., nintedanib and pirfenidone) slow but do not halt an inexorable decline in lung function, but at the price of substantial — and, for many patients, unacceptable — side . . .
Zitieren
APA
Taichman, D. (2026). Preserving Lung Function in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 395(2), 189-190. https://doi.org/10.1056/nejme2606821
Vancouver
Taichman D. Preserving Lung Function in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine. 2026;395(2):189-190. doi:10.1056/nejme2606821
BibTeX
@article{Taichman2026,
author = {Taichman, Darren},
title = {Preserving Lung Function in Idiopathic Pulmonary Fibrosis},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {2},
pages = {189--190},
doi = {10.1056/nejme2606821}
}
EUVIMED